Tech Company Inital Public Offerings
iTeos Therapeutics IPO
iTeos Therapeutics was acquired by . Shares were listed on 7/24/2020.
Transaction Overview
Company Name
Announced On
7/24/2020
Transaction Type
IPO
Amount
$201,100,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: for the clinical development of EOS-850, for the clinical development of EOS-448, for the development of other product candidates in our pipeline and our drug discovery programs; and the remainder for general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
139 Main St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
iTeos Therapeutics (Nasdaq: ITOS) is a next-generation immuno-oncology company developing innovative anti-cancer agents to fulfil the promise of immunotherapy by targeting the tumor microenvironment to improve the lives of people living with cancer. The Company is targeting two key pathways by which cancer cells suppress the immune system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michel Detheux
Chief Medical Officer
Joanne Lager
Chief Operating Officer
Matthew Call
VP - General Counsel
Gregory Sieczkiewicz
Browse more venture capital transactions:
Prev: 7/24/2020: Sidecar Health venture capital transaction
Next: 7/24/2020: Talkdesk venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs